Key result
Edoxaban for acute VTE shows a ~4% annual recurrence rate.
Why the study?
Long-term (>6 months), real-world evidence on the effectiveness and safety of edoxaban for VTE management, including data from South Korea and Taiwan, remained limited.
Does edoxaban prevent recurrent VTE and maintain safety in patients with acute VTE in a real-world setting?
Observational (n=277)
Yes
Does edoxaban prevent recurrent VTE and maintain safety in patients with acute VTE in a real-world setting?
In a real-world registry of patients from South Korea and Taiwan, edoxaban demonstrated low 12-month VTE recurrence and major bleeding rates, consistent with previous randomized controlled trials.
Addresses evidence gap for long-term edoxaban in Asian VTE patients; extends global ETNA-VTE programme to Korea and Taiwan.
Long-term (>6 months), real-world evidence on the effectiveness and safety of edoxaban for venous thromboembolism (VTE) management including data from South Korea and Taiwan remain limited. The global ETNA-VTE programme evaluated real-world outcomes of edoxaban-treated patients. ETNA-VTE-KOR-TWN was a multi-centre (20-site), prospective, observational, non-interventional, single-arm registry study (NCT02952599) evaluating edoxaban in patients with acute VTE (initial/recurrent), followed up for 12 months. Effectiveness outcomes—including VTE recurrence—safety, bleeding events, and hospitalisations were analysed and annualised rates (%/year) reported. Of 352 patients enrolled, 277 met inclusion criteria for the FAS (Taiwan: 119/277 [43.0%]; South Korea: 158/277 [57.0%]). The most prevalent index VTE was pulmonary embolism (n=133), followed by deep vein thrombosis (n=89) and both (n=55). Most patients received the 60-mg dose (67.1%), and these patients were younger (median age, 65 vs 76 years), with higher body weight (mean, 71.2 vs 58.3 kg) vs the 30-mg group. The overall annual VTE recurrence rate was 3.9%/y: it was 2.5%/y vs 6.9%/y in the 60-mg vs 30-mg group. None of the all-cause deaths (n=21) in the overall analysis were due to VTE. Hospitalisations due to cardiovascular-related events occurred in 25/277 patients (11.3%/y). Ischaemic/haemorrhagic stroke occurred in 2/277 patients (0.9%/y); overall bleeding events occurred in 29/277 patients (13.4%/y); and major bleeding events occurred in 3/277 patients (1.3%/y) in the overall analysis. The effectiveness and safety of edoxaban should be interpreted with caution due to the lack of a direct comparator arm including other oral anticoagulants. Rates of VTE recurrence, bleeding complications, and deaths in patients from South Korea and Taiwan were low and consistent with RCTs. • Edoxaban is effective in preventing recurrent VTE in a real-world setting • Low 12-month VTE recurrence rates were reported from South Korea and Taiwan • ETNA-VTE-KOR-TWN supports the favourable risk-benefit profile for edoxaban • The findings of this study align with previous reports from RCTs
No takes yet. Share an insight, caveat, or question.
Choi et al. (2026) conducted an observational in acute venous thromboembolism (VTE) (n=277). edoxaban was evaluated on VTE recurrence. Edoxaban use in patients with acute VTE in South Korea and Taiwan demonstrated an overall annual VTE recurrence rate of 3.9%/y over 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: